The global stereotactic radiation therapy market was valued at US$ 3.7 Billion in 2022 and is expected to reach US$ 7.9 Billion by 2033. The linear accelerator radiosurgery systems with around 68.9% value share, has topped the global market within the product category in 2022 and is expected to grow at a CAGR of close to 7.3% over the forecast period (2023 to 2033)
Market Outlook:
| Data Points | Market Insights |
|---|---|
| Market Value 2022 | US$ 3.7 Billion |
| Market Value 2023 | US$ 3.9 Billion |
| Market Value 2033 | US$ 7.9 Billion |
| CAGR 2023 to 2033 | 7.3% |
| Market Share of Top 5 Countries | 62.6% |
| Key Market Players | Mevion Medical Systems, Inc., Accuray Incorporated, MASEP Medical Science & Technology Development (Shenzhen) Co, Akesis, Inc., Elekta, Hitachi, Ltd. (Mitsubishi Electric Corporation), Siemens Healthineers AG (Varian Medical Systems, Inc.), Ion Beam Applications, ProTom International, Pronova Solutions, Sumitomo Heavy Industries, Ltd., Provision Cares, Optivus Proton Therapy Inc., Advanced Oncotherapy, Sun Nuclear Corporation, and B dot Medical Inc. (partnered with Toshiba) |
The treatment of functional disorders and tiny brain tumors with stereotactic radiosurgery (SRS), a non-surgical radiation therapy has been growing rapidly. In comparison to conventional therapy, it can administer precisely focused radiation in fewer high-dose treatments, helping to maintain healthy tissue. Stereotactic body radiation (SBRT) is the name of the procedure utilised for the treatment of body tumors using SRS.
Small brain tumors and other abnormalities in function of the brain were the original target conditions for the development of stereotactic radiosurgery (SRS), a very precise radiation therapy technique. Stereotactic body radiotherapy (SBRT) is a technique used to treat body tumors that uses the same concepts as cranial SRS, namely precise radiation with delivery accuracy to within one to two millimetres.
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
The global market for stereotactic radiation therapy (SRT) was around 55.3% of the overall US$ 6.6 Billion of the global radiation therapy market in 2022.
The rapid advancement of technology in the radiation therapy segment in recent years has pushed the expansion of the SRT market. The rising prevalence of cancer disorders and the growing geriatric population is driving the growing need for rapid improvement in SRT technology around the world.
The growing research for development of cost-effective stereotactic radiotherapy, and increasing awareness regarding radiotherapy are few other growth drivers increasing the demand for stereotactic radiation therapy. Globally, radiation therapy is the treatment of choice for over 7 out of 10 patients with cancers of the breast, head and neck, lung or oesophagus
There is a huge demand for radiation therapy systems in low and middle income countries as cancer kills more population than HIV, TB and malaria combines. This affects the lives of patients and their families with huge physical, emotional and financial crisis.
Increase in cancer cases and the sophistication of new treatment protocols drives the market for newly developed automated SRT systems which makes treatment rapid and cost-effective.
Owed to the above factors, the global market is projected to grow at CAGR of 7.3% in forecasted period.
For several decades, lung cancer has been the most frequent cancer in the world.
In a study conducted at the Markey Cancer Centre in 2021, stereotactic body radiation therapy (SBRT) was utilized for persons with stage I or stage II lung cancer who are not adequate for surgical procedure. Because X-rays are well focused and healthy tissue receives relatively little radiation, SBRT side effects are rare. This non-surgical therapy option with less side effects of the SBRT is enticing patients and clinicians to use it.
Stereotactic radiation therapy provides good tumor control rates while delivering precise doses. In comparison to conventional radiation therapy, it allows for larger radiation doses to be provided in fewer treatment sessions. This leads to better outcomes, such as higher tumor control rates and higher survival rates for some malignancies. The possibility of shorter treatment sessions and fewer side effects leads to the growing use of stereotactic radiation therapy.
Stereotactic radiation therapy is a non-invasive or minimally invasive therapeutic option that, in some situations, avoids the need for surgery. It can be used to treat both primary and metastatic tumors, offering a non-invasive alternative to invasive methods. Stereotactic radiation therapy is appealing to patients and physicians due to its ability to deliver targeted radiation without requiring open surgery.
All the above factors are expected to contribute as the driving forces for the market growth over forecast period.
Principal Consultant
Moving targets, such as tumors impacted by respiration or other physiological motion, can be difficult to target and track accurately in stereotactic radiation therapy. Techniques such as respiratory gating or tumor tracking may be used to solve this issue, but they complicate the treatment process and necessitate more resources.
Stereotactic radiation therapy necessitates extensive technical knowledge and specialised training. SRT's success is dependent on accurate treatment planning, target localization, and precision radiation delivery. Because of the complexities of the therapy procedure, trained radiation oncologists, medical physicists, and dosimetrists are required, which can be a constraint in some circumstances.
While stereotactic radiation therapy has demonstrated excellent short-term outcomes, there is a need for more long-term data on its effectiveness and potential late toxicities. Long-term follow-up studies are essential to evaluate the durability of tumor control and the impact on patient survival and quality of life. The limited availability of long-term data may influence decision-making and adoption of SRT in certain scenarios.
The U.S. occupies 33.7% of market share in 2022 globally. The growing prevalence of cancer and the need for effective treatment choices drive the demand for sophisticated radiation therapy techniques like stereotactic radiation therapy. As the incidence of cancer rises, so does the demand for precise and focused therapies such as stereotactic radiation therapy.
These factors, together with continuous research and clinical trials, continue to promote stereotactic radiation therapy's adoption and development as a key treatment technique in oncology and other medical sectors.
China expenditure on stereotactic radiation therapy in 2022 was US$ 272.8 Million.
China approaches healthcare collaboratively, with substantial relationships between hospitals, research institutions, and industrial players.
Ongoing SRT research and clinical trials help to enhance the evidence base and improve treatment methods. The good findings of these research are driving the use of SRT in clinical practise.
In 2022, the Germany held a significant share in the global market and contributed around US$ 318.1 Million. Germany has a well-developed healthcare system that includes cutting-edge medical facilities, hospitals, and research institutes. The availability of cutting-edge radiation treatment equipment and expertise facilitates the country's extensive adoption of SRT. Germany lays a great emphasis on providing patients with least invasive treatment choices. SRT is an outpatient, non-invasive technique that delivers very precise radiation to tumors, minimising the need for open surgery. The demand for non-invasive treatments corresponds to the expansion of the SRT market in Germany.
Germany is well-known for its medical technical breakthroughs. SRT has become more precise and effective as better imaging devices, treatment planning software, and real-time tumor tracking technologies have been developed and adopted. These technical improvements aid in the expansion of the SRT market in Germany.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
By technology, linear accelerator radiosurgery systems held 68.9% market share in world in 2022.
A linear accelerator radiation therapy tailors high-energy radiation such as x-rays or electrons to conform to the contour of a tumor to damage cancer cells while preserving normal tissue in the surrounding area. It has numerous built-in safety safeguards to ensure that it delivers the correct dose and is frequently examined by a medical physicist to confirm that it is functioning properly. This precise treatment use of technology is helping these therapies gain popularity.
CNS cancer held 24.5% market share in 2022 globally.
SRS reduces the risk of haemorrhage, infection, and anaesthesia associated with surgery. It is an outpatient procedure that involves little interruption of other therapies, like as chemotherapy. The outcomes of SRS for brain metastases or other CNS malignancies appear to be comparable to those of surgery to remove the tumor. This is the rationale for the widespread use of these technologies in CNS cancer treatment around the world.
The hospitals have a considerable presence in the stereotactic radiation therapy market, accounting for 42.2% value share in 2022, and exhibit a high CAGR of 6.2% over the forecast period. The increased use of SRT in hospitals is a result of more data generated during cancer diagnosis and treatment, as well as increased patient visits globally each year. Increasing government initiatives aimed at providing hospitals with cutting-edge technology are a few of the factors driving this market's expansion.
Collaboration in research & development, and commercialization to expand market and create technologically advanced systems with new-edge applications are key strategies adopted by key players. Numerous large firms compete in the field of stereotactic radiation therapy. Among the well-known players in this field are:
Similarly, recent developments related to the company’s manufacturing the stereotactic radiation therapy systems have been tracked by the team at Future Market Insights, which are available in the full report.
| Attribute | Details |
|---|---|
| Forecast Period | 2023 to 2033 |
| Historical Data Available for | 2017 to 2022 |
| Market Analysis | US$ Million for Value, Units for Volume |
| Key Regions Covered | North America, Latin America, Europe, South Asia, East Asia, Oceania, Middle East and Africa (MEA) |
| Key Countries Covered | USA, Canada, Brazil, Mexico, Argentina, Germany, Italy, France, UK, Spain, BENELUX, Russia, Nordics, China, Japan, South Korea, India, Indonesia, Thailand, Philippines, Vietnam, Malaysia, Australia, New Zealand, GCC countries, Türkiye, Israel, Northern Africa and South Africa. |
| Key Market Segments Covered | Technology, Indication, End User, and Region |
| Key Companies Profiled |
|
| Report Coverage | Market Forecast, Competition Intelligence, DROT Analysis, Market Dynamics and Challenges, Strategic Growth Initiatives |
| Pricing | Available upon Request |
The market is valued at US$ 3.9 billion in 2023.
The market is likely to register a CAGR of 7.3% from 2023 to 2033.
The market is projected to value at US$ 7.9 billion in 2033.
The market share of the top 5 countries is 62.6%.
Technological advancements in radiation therapy are likely to provide a boost to the market.
1. Executive Summary 1.1. Global Market Outlook 1.2. Demand Side Trends 1.3. Supply Side Trends 1.4. Analysis and Recommendations 2. Market Overview 2.1. Market Coverage / Taxonomy 2.2. Market Definition / Scope / Limitations 2.3. Inclusions & Exclusions 3. Key Market Trends 3.1. Key Trends Impacting the Market 3.2. Product Innovation / Development Trends 4. Value Added Insights 4.1. Product Adoption / Usage Analysis 4.2. Installed Base Scenario 4.3. Disease Epidemiology by Key Indications 4.4. Technology Assessment 4.5. Regulatory Scenario 4.6. Reimbursement Landscape 4.7. PESTLE Analysis 4.8. Porter’s Analysis 4.9. Value Chain Analysis 5. Market Background 5.1. Macro-Economic Factors 5.1.1. Global Healthcare Expenditure 5.1.2. Global Life Expectancy Outlook 5.1.3. Global Radiation Therapy Market Overview 5.2. Forecast Factors - Relevance & Impact 5.2.1. Top Companies Historical Growth 5.2.2. Technological Advancements in Stereotactic Radiation Therapy 5.2.3. New Product Launches 5.2.4. Ease of Treatment in Outpatient Basis 5.2.5. Improved Access to Healthcare Services 5.2.6. Increasing Minimally Invasive Treatment Options 5.2.7. Cost of Products 5.2.8. Increasing Prevalence of Cancer 5.2.9. Favorable Policies by Government 5.2.10. Strategic Mergers and Acquisitions among Players 5.3. Market Dynamics 5.3.1. Drivers 5.3.2. Restraints 5.3.3. Opportunity Analysis 6. Global Market Demand Volume Analysis 2017 –2022 and Forecast, 2023 to 2033 6.1. Historical Market Volume (Units) Analysis, 2017 –2022 6.2. Current and Future Market Volume (Units) Projections, 2023 to 2033 6.2.1. Y-o-Y Growth Trend Analysis 7. Global Market - Pricing Analysis 7.1. Regional Pricing Analysis, By-Product 7.2. Pricing Break Up 7.2.1. Manufacturer Level 7.2.2. Distributor Level 7.3. Global Average Pricing Analysis Benchmark 7.4. Pricing Assumptions 8. Global Market Demand (in Value or Size in US$ Million) Analysis 2017 to 2022 and Forecast, 2023 to 2033 8.1. Historical Market Value (US$ Million) Analysis, 2017 to 2022 8.2. Current and Future Market Value (US$ Million) Projections, 2023 to 2033 8.2.1. Y-o-Y Growth Trend Analysis 8.2.2. Absolute $ Opportunity Analysis 9. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, by Technology 9.1. Introduction / Key Findings 9.2. Historical Market Size (US$ Million) and Volume (Units) Analysis, By Technology, 2017 to 2022 9.3. Current and Future Market Size (US$ Million) and Volume (Units) Analysis and Forecast, By Technology, 2023 to 2033 9.3.1. Linear Accelerator Radiosurgery Systems 9.3.2. GammaKnife Radiosurgery Systems 9.3.3. Proton Beam Therapy 9.3.4. CyberKnife 9.4. Market Attractiveness Analysis, By Technology 10. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, by Indication 10.1. Introduction / Key Findings 10.2. Historical Market Size (US$ Million) and Volume (Units) Analysis, By Indication, 2017 to 2022 10.3. Current and Future Market Size (US$ Million) and Volume (Units) Analysis and Forecast, By Indication, 2023 to 2033 10.3.1. CNS Cancer 10.3.2. Prostate Cancer 10.3.3. Head and Neck 10.3.4. Breast Cancer 10.3.5. Lung Cancer 10.3.6. Other 10.4. Market Attractiveness Analysis, By Indication 11. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, by End User 11.1. Introduction / Key Findings 11.2. Historical Market Size (US$ Million) Analysis, By End User, 2017 to 2022 11.3. Current and Future Market Size (US$ Million) Analysis and Forecast, By End User, 2023 to 2033 11.3.1. Hospitals 11.3.2. Imaging Centers 11.3.3. Cancer Research Centers 11.3.4. Oncological Treatment Centers 11.4. Market Attractiveness Analysis, By End User 12. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, by Region 12.1. Introduction 12.2. Historical Market Size (US$ Million) and Volume (Units) Analysis, By Region, 2017 to 2022 12.3. Current and Future Market Size (US$ Million) and Volume (Units) Analysis and Forecast, By Region, 2023 to 2033 12.3.1. North America 12.3.2. Latin America 12.3.3. Europe 12.3.4. East Asia 12.3.5. South Asia 12.3.6. Oceania 12.3.7. Middle East and Africa (Middle East & Africa) 12.4. Market Attractiveness Analysis, By Region 13. North America Market Analysis 2017 to 2022 and Forecast 2023 to 2033 13.1. Introduction 13.2. Historical Market Size (US$ Million) and Volume (Units) Trend Analysis, By Market Taxonomy, 2017 to 2022 13.3. Current and Future Market Size (US$ Million) and Volume (Units) Analysis and Forecast, By Market Taxonomy, 2023 to 2033 13.3.1. By Country 13.3.1.1. U.S. 13.3.1.2. Canada 13.3.2. By Technology 13.3.3. By Indication 13.3.4. By End User 13.4. Market Attractiveness Analysis 13.4.1. By Country 13.4.2. By Technology 13.4.3. By Indication 13.4.4. By End User 13.5. Key Market Participants - Intensity Mapping 13.6. Drivers and Restraints - Impact Analysis 13.7. Market Trends 13.8. Country Level Analysis & Forecast 13.8.1. U.S. Market 13.8.1.1. Introduction 13.8.1.2. Market Analysis and Forecast, By Market Taxonomy 13.8.1.2.1. By Technology 13.8.1.2.2. By Indication 13.8.1.2.3. By End User 13.8.2. Canada Market 13.8.2.1. Introduction 13.8.2.2. Market Analysis and Forecast, By Market Taxonomy 13.8.2.2.1. By Technology 13.8.2.2.2. By Indication 13.8.2.2.3. By End User 14. Latin America Market Analysis 2017 to 2022 and Forecast 2023 to 2033 14.1. Introduction 14.2. Historical Market Size (US$ Million) and Volume (Units) Trend Analysis, By Market Taxonomy, 2017 to 2022 14.3. Current and Future Market Size (US$ Million) and Volume (Units) Analysis and Forecast, By Market Taxonomy, 2023 to 2033 14.3.1. By Country 14.3.1.1. Brazil 14.3.1.2. Mexico 14.3.1.3. Argentina 14.3.1.4. Rest of Latin America 14.3.2. By Technology 14.3.3. By Indication 14.3.4. By End User 14.4. Market Attractiveness Analysis 14.4.1. By Country 14.4.2. By Technology 14.4.3. By Indication 14.4.4. By End User 14.5. Key Market Participants - Intensity Mapping 14.6. Drivers and Restraints - Impact Analysis 14.7. Market Trends 14.8. Country Level Analysis & Forecast 14.8.1. Brazil Market 14.8.1.1. Introduction 14.8.1.2. Market Analysis and Forecast, By Market Taxonomy 14.8.1.2.1. By Technology 14.8.1.2.2. By Indication 14.8.1.2.3. By End User 14.8.2. Argentina Market 14.8.2.1. Introduction 14.8.2.2. Market Analysis and Forecast, By Market Taxonomy 14.8.2.2.1. By Technology 14.8.2.2.2. By Indication 14.8.2.2.3. By End User 14.8.3. Mexico Market 14.8.3.1. Introduction 14.8.3.2. Market Analysis and Forecast, By Market Taxonomy 14.8.3.2.1. By Technology 14.8.3.2.2. By Indication 14.8.3.2.3. By End User 15. Europe Market Analysis 2017 to 2022 and Forecast 2023 to 2033 15.1. Introduction 15.2. Historical Market Size (US$ Million) and Volume (Units) Trend Analysis, By Market Taxonomy, 2017 to 2022 15.3. Current and Future Market Size (US$ Million) and Volume (Units) Analysis and Forecast, By Market Taxonomy, 2023 to 2033 15.3.1. By Country 15.3.1.1. Germany 15.3.1.2. Italy 15.3.1.3. France 15.3.1.4. U.K. 15.3.1.5. Spain 15.3.1.6. BENELUX 15.3.1.7. Nordic Countries 15.3.1.8. Russia 15.3.1.9. Rest of Europe 15.3.2. By Technology 15.3.3. By Indication 15.3.4. By End User 15.4. Market Attractiveness Analysis 15.4.1. By Country 15.4.2. By Technology 15.4.3. By Indication 15.4.4. By End User 15.5. Key Market Participants - Intensity Mapping 15.6. Drivers and Restraints - Impact Analysis 15.7. Market Trends 15.8. Country Level Analysis & Forecast 15.8.1. Germany Market 15.8.1.1. Introduction 15.8.1.2. Market Analysis and Forecast, By Market Taxonomy 15.8.1.2.1. By Technology 15.8.1.2.2. By Indication 15.8.1.2.3. By End User 15.8.2. France Market 15.8.2.1. Introduction 15.8.2.2. Market Analysis and Forecast, By Market Taxonomy 15.8.2.2.1. By Technology 15.8.2.2.2. By Indication 15.8.2.2.3. By End User 15.8.3. Italy Market 15.8.3.1. Introduction 15.8.3.2. Market Analysis and Forecast, By Market Taxonomy 15.8.3.2.1. By Technology 15.8.3.2.2. By Indication 15.8.3.2.3. By End User 15.8.4. Spain Market 15.8.4.1. Introduction 15.8.4.2. Market Analysis and Forecast, By Market Taxonomy 15.8.4.2.1. By Technology 15.8.4.2.2. By Indication 15.8.4.2.3. By End User 15.8.5. U.K. Market 15.8.5.1. Introduction 15.8.5.2. Market Analysis and Forecast, By Market Taxonomy 15.8.5.2.1. By Technology 15.8.5.2.2. By Indication 15.8.5.2.3. By End User 15.8.6. BENELUX Market 15.8.6.1. Introduction 15.8.6.2. Market Analysis and Forecast, By Market Taxonomy 15.8.6.2.1. By Technology 15.8.6.2.2. By Indication 15.8.6.2.3. By End User 15.8.7. Nordic Countries Market 15.8.7.1. Introduction 15.8.7.2. Market Analysis and Forecast, By Market Taxonomy 15.8.7.2.1. By Technology 15.8.7.2.2. By Indication 15.8.7.2.3. By End User 15.8.8. Russia Market 15.8.8.1. Introduction 15.8.8.2. Market Analysis and Forecast, By Market Taxonomy 15.8.8.2.1. By Technology 15.8.8.2.2. By Indication 15.8.8.2.3. By End User 16. South Asia Market Analysis 2017 to 2022 and Forecast 2023 to 2033 16.1. Introduction 16.2. Historical Market Size (US$ Million) and Volume (Units) Trend Analysis, By Market Taxonomy, 2017 to 2022 16.3. Current and Future Market Size (US$ Million) and Volume (Units) Analysis and Forecast, By Market Taxonomy, 2023 to 2033 16.3.1. By Country 16.3.1.1. India 16.3.1.2. Thailand 16.3.1.3. Indonesia 16.3.1.4. Malaysia 16.3.1.5. Vietnam 16.3.1.6. Philippines 16.3.1.7. Rest of South Asia 16.3.2. By Technology 16.3.3. By End User 16.4. Market Attractiveness Analysis 16.4.1. By Country 16.4.2. By Technology 16.4.3. By Indication 16.4.4. By End User 16.5. Key Market Participants - Intensity Mapping 16.6. Drivers and Restraints - Impact Analysis 16.7. Market Trends 16.8. Country Level Analysis & Forecast 16.8.1. India Market 16.8.1.1. Introduction 16.8.1.2. Market Analysis and Forecast, By Market Taxonomy 16.8.1.2.1. By Technology 16.8.1.2.2. By Indication 16.8.1.2.3. By End User 16.8.2. Indonesia Market 16.8.2.1. Introduction 16.8.2.2. Market Analysis and Forecast, By Market Taxonomy 16.8.2.2.1. By Technology 16.8.2.2.2. By Indication 16.8.2.2.3. By End User 16.8.3. Malaysia Market 16.8.3.1. Introduction 16.8.3.2. Market Analysis and Forecast, By Market Taxonomy 16.8.3.2.1. By Technology 16.8.3.2.2. By Indication 16.8.3.2.3. By End User 16.8.4. Thailand Market 16.8.4.1. Introduction 16.8.4.2. Market Analysis and Forecast, By Market Taxonomy 16.8.4.2.1. By Technology 16.8.4.2.2. By Indication 16.8.4.2.3. By End User 16.8.5. Vietnam Market 16.8.5.1. Introduction 16.8.5.2. Market Analysis and Forecast, By Market Taxonomy 16.8.5.2.1. By Technology 16.8.5.2.2. By Indication 16.8.5.2.3. By End User 16.8.6. Philippines Market 16.8.6.1. Introduction 16.8.6.2. Market Analysis and Forecast, By Market Taxonomy 16.8.6.2.1. By Technology 16.8.6.2.2. By Indication 16.8.6.2.3. By End User 17. East Asia Market Analysis 2017 to 2022 and Forecast 2023 to 2033 17.1. Introduction 17.2. Historical Market Size (US$ Million) and Volume (Units) Trend Analysis, By Market Taxonomy, 2017 to 2022 17.3. Current and Future Market Size (US$ Million) and Volume (Units) Analysis and Forecast, By Market Taxonomy, 2023 to 2033 17.3.1. By Country 17.3.1.1. China 17.3.1.2. Japan 17.3.1.3. South Korea 17.3.2. By Technology 17.3.3. By Indication 17.3.4. By End User 17.4. Market Attractiveness Analysis 17.4.1. By Country 17.4.2. By Technology 17.4.3. By Indication 17.4.4. By End User 17.5. Key Market Participants - Intensity Mapping 17.6. Drivers and Restraints - Impact Analysis 17.7. Market Trends 17.8. Country Level Analysis & Forecast 17.8.1. China Market 17.8.1.1. Introduction 17.8.1.2. Market Analysis and Forecast, By Market Taxonomy 17.8.1.2.1. By Technology 17.8.1.2.2. By Indication 17.8.1.2.3. By End User 17.8.2. Japan Market 17.8.2.1. Introduction 17.8.2.2. Market Analysis and Forecast, By Market Taxonomy 17.8.2.2.1. By Technology 17.8.2.2.2. By Indication 17.8.2.2.3. By End User 17.8.3. South Korea Market 17.8.3.1. Introduction 17.8.3.2. Market Analysis and Forecast, By Market Taxonomy 17.8.3.2.1. By Technology 17.8.3.2.2. By Indication 17.8.3.2.3. By End User 18. Oceania Market Analysis 2017 to 2022 and Forecast 2023 to 2033 18.1. Introduction 18.2. Historical Market Size (US$ Million) and Volume (Units) Trend Analysis, By Market Taxonomy, 2017 to 2022 18.3. Current and Future Market Size (US$ Million) and Volume (Units) Analysis and Forecast, By Market Taxonomy, 2023 to 2033 18.3.1. By Country 18.3.1.1. Australia 18.3.1.2. New Zealand 18.3.2. By Technology 18.3.3. By Indication 18.3.4. By End User 18.4. Market Attractiveness Analysis 18.4.1. By Country 18.4.2. By Technology 18.4.3. By Indication 18.4.4. By End User 18.5. Key Market Participants - Intensity Mapping 18.6. Drivers and Restraints - Impact Analysis 18.7. Market Trends 18.8. Country Level Analysis & Forecast 18.8.1. Australia Market 18.8.1.1. Introduction 18.8.1.2. Market Analysis and Forecast, By Market Taxonomy 18.8.1.2.1. By Technology 18.8.1.2.2. By Indication 18.8.1.2.3. By End User 18.8.2. New Zealand Market 18.8.2.1. Introduction 18.8.2.2. Market Analysis and Forecast, By Market Taxonomy 18.8.2.2.1. By Technology 18.8.2.2.2. By Indication 18.8.2.2.3. By End User 19. Middle East and Africa (Middle East & Africa) Market Analysis 2017 to 2022 and Forecast 2023 to 2033 19.1. Introduction 19.2. Historical Market Size (US$ Million) and Volume (Units) Trend Analysis, By Market Taxonomy, 2017 to 2022 19.3. Current and Future Market Size (US$ Million) and Volume (Units) Analysis and Forecast, By Market Taxonomy, 2023 to 2033 19.3.1. By Country 19.3.1.1. GCC Countries 19.3.1.2. Israel 19.3.1.3. Türkiye 19.3.1.4. Northern Africa 19.3.1.5. South Africa 19.3.1.6. Rest of Middle East and Africa 19.3.2. By Technology 19.3.3. By Indication 19.3.4. By End User 19.4. Market Attractiveness Analysis 19.4.1. By Country 19.4.2. By Technology 19.4.3. By Indication 19.4.4. By End User 19.5. Key Market Participants - Intensity Mapping 19.6. Drivers and Restraints - Impact Analysis 19.7. Market Trends 19.8. Country Level Analysis & Forecast 19.8.1. GCC Countries Market 19.8.1.1. Introduction 19.8.1.2. Market Analysis and Forecast, By Market Taxonomy 19.8.1.2.1. By Technology 19.8.1.2.2. By Indication 19.8.1.2.3. By End User 19.8.2. Israel Market 19.8.2.1. Introduction 19.8.2.2. Market Analysis and Forecast, By Market Taxonomy 19.8.2.2.1. By Technology 19.8.2.2.2. By Indication 19.8.2.2.3. By End User 19.8.3. Türkiye Market 19.8.3.1. Introduction 19.8.3.2. Market Analysis and Forecast, By Market Taxonomy 19.8.3.2.1. By Technology 19.8.3.2.2. By Indication 19.8.3.2.3. By End User 19.8.4. Northern Africa Market 19.8.4.1. Introduction 19.8.4.2. Market Analysis and Forecast, By Market Taxonomy 19.8.4.2.1. By Technology 19.8.4.2.2. By Indication 19.8.4.2.3. By End User 19.8.5. South Africa Market 19.8.5.1. Introduction 19.8.5.2. Market Analysis and Forecast, By Market Taxonomy 19.8.5.2.1. By Technology 19.8.5.2.2. By Indication 19.8.5.2.3. By End User 20. Market Structure Analysis 20.1. Market Analysis, By Tier of Companies 20.2. Market Share Analysis of Top Players 20.3. Market Concentration 20.4. Market Presence Analysis 20.4.1. Regional Footprint Analysis 20.4.2. Product Footprint Analysis 20.4.3. Channel Footprint Analysis 21. Competition Analysis 21.1. Competition Dashboard 21.2. Branding and Promotional Strategies, By Key Players 21.3. Key Development Analysis 21.4. Competition Deep Dive 21.4.1. Mevion Medical Systems, Inc. 21.4.1.1. Overview 21.4.1.2. Product Portfolio 21.4.1.3. Key Financials 21.4.1.4. SWOT Analysis 21.4.1.5. Sales Footprint 21.4.1.6. Strategy Overview 21.4.1.7. Key Developments 21.4.1.7.1. Marketing Strategies 21.4.1.7.2. Product Strategies 21.4.1.7.3. Channel Strategies 21.4.2. Accuray Incorporated 21.4.2.1. Overview 21.4.2.2. Product Portfolio 21.4.2.3. Key Financials 21.4.2.4. SWOT Analysis 21.4.2.5. Sales Footprint 21.4.2.6. Strategy Overview 21.4.2.7. Key Developments 21.4.2.7.1. Marketing Strategies 21.4.2.7.2. Product Strategies 21.4.2.7.3. Channel Strategies 21.4.3. MASEP Medical Science & Technology Development (Shenzhen) Co 21.4.3.1. Overview 21.4.3.2. Product Portfolio 21.4.3.3. Key Financials 21.4.3.4. SWOT Analysis 21.4.3.5. Sales Footprint 21.4.3.6. Strategy Overview 21.4.3.7. Key Developments 21.4.3.7.1. Marketing Strategies 21.4.3.7.2. Product Strategies 21.4.3.7.3. Channel Strategies 21.4.4. Akesis, Inc 21.4.4.1. Overview 21.4.4.2. Product Portfolio 21.4.4.3. Key Financials 21.4.4.4. SWOT Analysis 21.4.4.5. Sales Footprint 21.4.4.6. Strategy Overview 21.4.4.7. Key Developments 21.4.4.7.1. Marketing Strategies 21.4.4.7.2. Product Strategies 21.4.4.7.3. Channel Strategies 21.4.5. Elekta 21.4.5.1. Overview 21.4.5.2. Product Portfolio 21.4.5.3. Key Financials 21.4.5.4. SWOT Analysis 21.4.5.5. Sales Footprint 21.4.5.6. Strategy Overview 21.4.5.7. Key Developments 21.4.5.7.1. Marketing Strategies 21.4.5.7.2. Product Strategies 21.4.5.7.3. Channel Strategies 21.4.6. Hitachi, Ltd. (Mitsubishi Electric Corporation) 21.4.6.1. Overview 21.4.6.2. Product Portfolio 21.4.6.3. Key Financials 21.4.6.4. SWOT Analysis 21.4.6.5. Sales Footprint 21.4.6.6. Strategy Overview 21.4.6.7. Key Developments 21.4.6.7.1. Marketing Strategies 21.4.6.7.2. Product Strategies 21.4.6.7.3. Channel Strategies 21.4.7. Siemens Healthineers AG (Varian Medical Systems, Inc.) 21.4.7.1. Overview 21.4.7.2. Product Portfolio 21.4.7.3. Key Financials 21.4.7.4. SWOT Analysis 21.4.7.5. Sales Footprint 21.4.7.6. Strategy Overview 21.4.7.7. Key Developments 21.4.7.7.1. Marketing Strategies 21.4.7.7.2. Product Strategies 21.4.7.7.3. Channel Strategies 21.4.8. Ion Beam Applications 21.4.8.1. Overview 21.4.8.2. Product Portfolio 21.4.8.3. Key Financials 21.4.8.4. SWOT Analysis 21.4.8.5. Sales Footprint 21.4.8.6. Strategy Overview 21.4.8.7. Key Developments 21.4.8.7.1. Marketing Strategies 21.4.8.7.2. Product Strategies 21.4.8.7.3. Channel Strategies 21.4.9. ProTom International 21.4.9.1. Overview 21.4.9.2. Product Portfolio 21.4.9.3. Key Financials 21.4.9.4. SWOT Analysis 21.4.9.5. Sales Footprint 21.4.9.6. Strategy Overview 21.4.9.7. Key Developments 21.4.9.7.1. Marketing Strategies 21.4.9.7.2. Product Strategies 21.4.9.7.3. Channel Strategies 21.4.10. Pronova Solutions 21.4.10.1. Overview 21.4.10.2. Product Portfolio 21.4.10.3. Key Financials 21.4.10.4. SWOT Analysis 21.4.10.5. Sales Footprint 21.4.10.6. Strategy Overview 21.4.10.7. Key Developments 21.4.10.7.1. Marketing Strategies 21.4.10.7.2. Product Strategies 21.4.10.7.3. Channel Strategies 21.4.11. Sumitomo Heavy Industries, Ltd. 21.4.11.1. Overview 21.4.11.2. Product Portfolio 21.4.11.3. Key Financials 21.4.11.4. SWOT Analysis 21.4.11.5. Sales Footprint 21.4.11.6. Strategy Overview 21.4.11.7. Key Developments 21.4.11.7.1. Marketing Strategies 21.4.11.7.2. Product Strategies 21.4.11.7.3. Channel Strategies 21.4.12. Provision Cares 21.4.12.1. Overview 21.4.12.2. Product Portfolio 21.4.12.3. Key Financials 21.4.12.4. SWOT Analysis 21.4.12.5. Sales Footprint 21.4.12.6. Strategy Overview 21.4.12.7. Key Developments 21.4.12.7.1. Marketing Strategies 21.4.12.7.2. Product Strategies 21.4.12.7.3. Channel Strategies 21.4.13. Optivus Proton Therapy Inc. 21.4.13.1. Overview 21.4.13.2. Product Portfolio 21.4.13.3. Key Financials 21.4.13.4. SWOT Analysis 21.4.13.5. Sales Footprint 21.4.13.6. Strategy Overview 21.4.13.7. Key Developments 21.4.13.7.1. Marketing Strategies 21.4.13.7.2. Product Strategies 21.4.13.7.3. Channel Strategies 21.4.14. Advanced Oncotherapy 21.4.14.1. Overview 21.4.14.2. Product Portfolio 21.4.14.3. Key Financials 21.4.14.4. SWOT Analysis 21.4.14.5. Sales Footprint 21.4.14.6. Strategy Overview 21.4.14.7. Key Developments 21.4.14.7.1. Marketing Strategies 21.4.14.7.2. Product Strategies 21.4.14.7.3. Channel Strategies 21.4.15. Sun Nuclear Corporation 21.4.15.1. Overview 21.4.15.2. Product Portfolio 21.4.15.3. Key Financials 21.4.15.4. SWOT Analysis 21.4.15.5. Sales Footprint 21.4.15.6. Strategy Overview 21.4.15.7. Key Developments 21.4.15.7.1. Marketing Strategies 21.4.15.7.2. Product Strategies 21.4.15.7.3. Channel Strategies 21.4.16. B dot Medical Inc. (partnered with Toshiba) 21.4.16.1. Overview 21.4.16.2. Product Portfolio 21.4.16.3. Key Financials 21.4.16.4. SWOT Analysis 21.4.16.5. Sales Footprint 21.4.16.6. Strategy Overview 21.4.16.7. Key Developments 21.4.16.7.1. Marketing Strategies 21.4.16.7.2. Product Strategies 21.4.16.7.3. Channel Strategies 22. Assumptions and Acronyms Used 23. Research Methodology
Explore Healthcare Insights
View Reports
Stereotactic Radiation Therapy Market
